Abstract
Immune checkpoint inhibitors are considered standard second-line treatment in advanced non-small cell lung cancer patients. This strategy has also become standard in first-line setting for a subgroup of patients with strongly positive PD-L1 tumors; therefore, PD-L1 status might be considered a new biomarker that deserves upfront testing. New combinations of immune checkpoint inhibitors and with chemotherapy have been tested in first-line treatment. However, some questions remain unanswered such as the best treatment strategy or the real upfront efficacy of these therapeutic strategies in the whole lung cancer population. In this review we summarize the main results in the first-line setting of recent phase III trials with immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
Keywords:
First-line; Immunotherapy; Nivolumab; Non-small cell lung cancer; Pembrolizumab.
Copyright © 2017 Elsevier B.V. All rights reserved.
MeSH terms
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antibodies, Monoclonal, Humanized / pharmacology
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Antineoplastic Agents / therapeutic use
-
B7-H1 Antigen / metabolism
-
Carcinoma, Non-Small-Cell Lung / drug therapy
-
Carcinoma, Non-Small-Cell Lung / immunology*
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Clinical Trials, Phase III as Topic
-
Humans
-
Immunotherapy / methods*
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / immunology
-
Lung Neoplasms / pathology
-
Nivolumab
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
-
Randomized Controlled Trials as Topic
-
Survival Analysis
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
B7-H1 Antigen
-
CD274 protein, human
-
Programmed Cell Death 1 Receptor
-
Nivolumab
-
pembrolizumab